The long-term goal of the Prostate Cancer (PC) Program is to elucidate the pathogenesis of prostatecancer and implement novel approaches to its prevention, early diagnosis, and individualized treatment. Toachieve these ends, the following Specific Goals will be pursued: 1) The molecular oncology of prostatecancer will be elucidated by defining the molecular lesions of proto-oncogenes and tumor suppressorgenes that are responsible for tumor formation; 2) Experimental models of prostate cancer will bedeveloped and characterized to elucidate critical regulatory networks, enhance preclinical studies, anddefine new biological endpoints, including the mechanisms of resistance to certain treatments;3) The experimental therapeutics of prostate cancer will be refined by using molecular determinants tooptimize clinical trials and thereby generate novel decision-making tools for disease management.The PC Program replaces the former Urologic Malignancies Program. It now consists of 19 members (12full members, 4 clinical members, and 3 associate members) from 6 departments within the College ofPhysicians & Surgeons at Columbia University (CD). Compared to the Urologic Malignancies Program, thenew PC Program has fewer members and their interests are more sharply focused on prostate cancer.New leadership has been brought into the Program, with Carlos Cordon-Cardo serving as Program Leaderand Daniel Petrylak as Co-Leader. In the past ten months, major investments by the HICCC led to therecruitment of Dr. Cordon-Cardo, as well a several other outstanding basic and translational investigators,including Edward Gelmann, Cory Abate-Shen, and Michael Shen.The comprehensive nature of the restructured PC Program now ranges from chemoprevention to novelchemotherapy, surgical oncology including minimal invasive procedures, radiation therapy, and quality ofcare programs. The number of trials and the number of patients accrued to such trials have increased.Approximately 78% of clinical trial accruals are of African American or Hispanic ethnicity. Severalinvestigators lead local and multi-center clinical trials. For the last budget year of the grant (July 1, 2006 -June 30, 2007), the PC Program received a total of $7.4M (direct costs) in cancer-relevant grant support,including $1.9M (direct costs) in NCI funding, $1.7M (direct costs) in other cancer-related peer-reviewedfunding, and $3.8M (direct costs) in cancer-related non-peer-reviewed funding. The total number ofpublications since the previous submission was 172, of which 23% were intra-programmatic and 12% interprogrammatic.
| DiCarlo, James E; Mahajan, Vinit B; Tsang, Stephen H (2018) Gene therapy and genome surgery in the retina. J Clin Invest 128:2177-2188 |
| Wert, Katherine J; Velez, Gabriel; Cross, Madeline R et al. (2018) Extracellular superoxide dismutase (SOD3) regulates oxidative stress at the vitreoretinal interface. Free Radic Biol Med 124:408-419 |
| Lee, Andreia; CingÖz, Oya; Sabo, Yosef et al. (2018) Characterization of interaction between Trim28 and YY1 in silencing proviral DNA of Moloney murine leukemia virus. Virology 516:165-175 |
| Schrank, Benjamin R; Aparicio, Tomas; Li, Yinyin et al. (2018) Nuclear ARP2/3 drives DNA break clustering for homology-directed repair. Nature 559:61-66 |
| Proto, Jonathan D; Doran, Amanda C; Gusarova, Galina et al. (2018) Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution. Immunity 49:666-677.e6 |
| Hernandez, Celine; Huebener, Peter; Pradere, Jean-Philippe et al. (2018) HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest 128:2436-2451 |
| Lee, Younghyun; Pujol Canadell, Monica; Shuryak, Igor et al. (2018) Candidate protein markers for radiation biodosimetry in the hematopoietically humanized mouse model. Sci Rep 8:13557 |
| Kraakman, Michael J; Liu, Qiongming; Postigo-Fernandez, Jorge et al. (2018) PPAR? deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects. J Clin Invest 128:2600-2612 |
| Cui, Xuan; Jauregui, Ruben; Park, Karen Sophia et al. (2018) Multimodal characterization of a novel mutation causing vitamin B6-responsive gyrate atrophy. Ophthalmic Genet 39:512-516 |
| Evans, Lucy P; Newell, Elizabeth A; Mahajan, MaryAnn et al. (2018) Acute vitreoretinal trauma and inflammation after traumatic brain injury in mice. Ann Clin Transl Neurol 5:240-251 |
Showing the most recent 10 out of 331 publications
